Introduction: We analyzed randomized clinical trials (RCTs) evaluating the efficacy of combined therapy with low-level light therapy (LLLT) and topical minoxidil for treatment of androgenetic alopecia (AGA). Methods: A literature search within PubMed identified RCTs evaluating hair regrowth following LLLT and minoxidil. Selection criteria were 600–1,100 nm wavelengths, treatment time ≥16 weeks, and objective evaluation for hair regrowth. Results: Five RCTs compared LLLT with minoxidil (2% or 5%) to 5% minoxidil treatment or LLLT treatment. One study showed combination therapy of LLLT, and 5% minoxidil improved hair density more than monotherapy. Another found combination LLLT with 2% minoxidil induced hair regrowth equivalent to 5% minoxidil. Similarly, another study described LLLT with 5% minoxidil versus minoxidil monotherapy to increase the number of hairs with no statistical difference between groups. One trial found that combination group increased hair regrowth in the first 2 months. The last study found a statistically significant increase in hair density with combined therapy compared to monotherapy. Conclusion: The studies describe either superiority or equivalence of combination therapy to minoxidil monotherapy for AGA. Early outcomes appear to support the superiority of combination therapy, but this advantage wanes at the end of the study periods.

Traditional treatments for androgenetic alopecia (AGA) have been based on finasteride and minoxidil, which are the only two FDA-approved medications. Finasteride inhibits the type II 5a-reductase, and daily oral intake of 1 mg finasteride has been shown to reduce systemic levels of DHT and increase hair counts in AGA [1]. Dutasteride, which inhibits both types I and II 5a-reductase, is also effective but has not yet undergone FDA approval [2]. Minoxidil is a topical and oral treatment for AGA, and its exact mechanism is postulated to be centered around its ability to open ATP-gated potassium channels in cell membranes leading to vasodilation, progression to the G1 stage of the cell cycle, cellular proliferation, and ultimately hair growth [3‒5]. Minoxidil is converted to its active component minoxidil sulfate through a sulfotransferase located within hair follicles. Topical minoxidil has been shown to reduce the length of the anagen phase and extend the length of the telogen phase [6]. Evidence of hair growth following topical minoxidil therapy has been shown to occur within six to 8 weeks, and has been hypothesized to be from minoxidil facilitating the conversion of follicles in the latent telogen phase to enter into anagen phase [6]. Studies have shown that minoxidil prolongs the anagen phase in the dermal papilla through upregulating β-catenin and stimulating follicular proliferation and differentiation [7]. Topical minoxidil has been associated with adverse effects including allergic contact dermatitis, hypertrichosis, and irritation [8]. Both interventions require long-term therapy but yield diminishing improvement in hair growth and are associated with long-term side effects. A 5-year follow-up study examining minoxidil treatment in men with AGA found that hair growth peaked at 1 year followed by a slow decline in hair growth [9]. Given the limited efficacy of long-term minoxidil use as well as adverse effects that render long-term compliance difficulty, alternative therapies that offer a more favorable side effect profile are the subject of ongoing clinical research. Potential therapies that offer synergistic results with existing therapies such as minoxidil could also prove useful.

Low-level light therapy (LLLT) is a relatively recent development for the treatment of AGA. LLLT, defined by a wavelength range of 600–1,100 nm, is a simple way of treating hair loss which can be done from home and has a better side effect profile. It is hypothesized that LLLT improves hair growth by stimulating anagen phase reentry in telogen hair follicles, prolonging the duration of anagen phase, and preventing premature entry of anagen hairs to catagen phase [4, 10, 11]. Additionally, it has been shown that LLLT plays an important role in reducing inflammatory cytokines while promoting favorable growth factors for hair growth [12].

While the individual effects of topical minoxidil and LLLT have been examined in previous studies, the focus of this review will be to discuss some of the newest results with combined topical minoxidil and LLLT compared to monotherapy alone. Given that both minoxidil and LLLT act through different mechanisms, evaluating the two treatments together to assess for possible synergy or improved efficacy in patients with AGA could be valuable.

Literature Search

A systematic review of the literature from 2015 to 2022 was performed in January 2022 using the PubMed, Embase, and Medline databases (Fig. 1). Double-blinded randomized controlled studies that assess the use of LLLT and topical minoxidil in combination to treat AGA were included. The databases were searched using different combinations of the following keywords: low level laser therapy, androgenetic alopecia, minoxidil, hair loss, hair regrowth, low level light therapy, and combined therapy.

Fig. 1.

Identification of appropriate studies for analysis. Flowchart depicting the exclusion processes for the identification of studies that are included in this review.

Fig. 1.

Identification of appropriate studies for analysis. Flowchart depicting the exclusion processes for the identification of studies that are included in this review.

Close modal

Inclusion and Exclusion Criteria

All search results from both databases were reviewed for relevant studies. Full text of relevant studies was reviewed to determine appropriateness according to established inclusion criteria. Case reports and case series were excluded. Articles were recognized as appropriate when they (a) included human subjects, (b) used a wavelength between 600 and 1,100 nm, (c) had a control group, (d) used an objective measure for hair regrowth, and (e) involved a 16-week or greater randomized double-blinded control trial. Studies that were published but violated any of these criteria, particularly the wavelength parameters previously set forth, were not evaluated in this review.

In total, 5 randomized control trials met our inclusion criteria comparing LLLT with topical 5% or 2% minoxidil to either a control group with no treatment, 5% minoxidil only treatment group, or LLLT only group (Table 1). Study populations varied with two studies using only men, two studies using only women, and one study using both men and women.

Table 1.

Summary of studies examining the efficacy of combined therapy versus monotherapy

 Summary of studies examining the efficacy of combined therapy versus monotherapy
 Summary of studies examining the efficacy of combined therapy versus monotherapy

Esmat et al. [13] conducted a randomized, double-blind, control trial examining 45 adult female patients with confirmed diagnosis of FPHL. Patients were divided randomly into 3 treatment groups receiving the iGrow helmet (wavelength of 650–675 nm), a combination of both 5% minoxidil daily and LLLT for 3 days weekly, or topical minoxidil 5% for 4 months. At 2 months, statistically significant increase in the number of hair follicles was only seen in the combined group, while the other two groups showed nonsignificant findings. At 4 months, the combined group and the LLLT treatment groups both showed a statistically significant increase in the number of follicles, with the combined group showing the greatest increase. According to self-reported patient satisfaction scoring, the combined LLLT and minoxidil treatment group reported the highest personal satisfaction with the results (p = 0.027).

Liu et al. [14] conducted a randomized, double-blinded, controlled trial examining 90 women with FPHL. Patients were randomly divided into three groups: one group received LLLT using the iHelmet device (650 nm), one group used topical 5% minoxidil daily, and the final group received both topical 5% minoxidil and LLLT. Hair density and hair thickness were evaluated using standardized phototrichograms recorded at baseline, 3 months, and 6 months. Hair density was found to be significantly increased in the combination group compared to the minoxidil only group (p = 0.036) and the LLLT only group (p = 0.012). Hair diameter was also found to be increased in the combined group compared to the minoxidil group (p = 0.036) and LLLT group (p = 0.048). There was no significant difference in self-reported patient satisfaction between the treatment groups.

Faghihi et al. [15] performed a randomized double-blind clinical trial examining 50 male and female patients with AGA randomly divided into a treatment group that received topical 5% minoxidil solution for 6 months plus LLLT (wavelength 785 nm) for 24 weeks. This was compared against a control group receiving only topical 5% minoxidil with a sham device as placebo. At 3 months, no significant difference in hair growth between the treatment and control groups was noted. Importantly, at 6, 9, and 12 months a statistically significant increase in percentage of hair recovery was seen in the treatment group (5% minoxidil + LLLT (p < 0.001). The treatment group was found to have an increased hair count compared to control (5% minoxidil + sham placebo) at months 9 and 12 (p < 0.001). There was a significant increase in hair diameter at 12 months in the treatment group compared to control (p = 0.045). Lastly, the authors found a statistically significant mean increase in hair count in the treatment group (78%) compared to control (51.3%) (p < 0.001).

Ferrara et al. [16] examined 21 male patients with AGA who were treated with LLLT using Capellux (wavelength 650 nm) followed by topical 5% minoxidil solution for 6 months. In this split scalp study, the LLLT device was altered such that it only emitted therapy to half the scalp region, and the other half of the device was shut off. The efficacy of treatment was assessed by clinical photos and automated trichograms taken at baseline, 3 months, and 6 months. The researchers found that both the combination therapy side of the scalp and the minoxidil monotherapy increased in total hair count, but the difference was not statistically significant (p > 0.05).

Mahe et al. [17] examined the effect of LLLT/GentleWaves devices (primary wavelength 590 nm and secondary 870 nm) and topical minoxidil therapy in 112 males with AGA. 45 patients received whole head exposure of LLLT combined with topical 2% minoxidil daily for 6 months. In the second treatment group, 45 patients applied topical 5% minoxidil for 6 months. The control group was 22 patients who did not receive any treatment. The researchers reported a similar increase in hair density in the combined treatment group and the 5% minoxidil treatment group compared to control. Notably, at 6 months, the rate of increase in hair growth began to decrease in the 5% minoxidil group but was sustained in the combination group.

Minoxidil therapy has consistently demonstrated modest therapeutic effects at improving hair growth and is usually used in either 2% or 5% topical formulations (Table 2). Goren and Naccarato [18] reported that following twice daily topical application of minoxidil, less than 40% of patients regrow hair. The prolonged treatment course and delayed onset of results are barriers to long-term minoxidil use. Other barriers to long-term compliance are adverse effects of minoxidil including scalp pruritis, contact dermatitis, scaling, and hypertrichosis in undesirable areas such as the forehead. Additionally, topical therapy with minoxidil can cause a shedding period, which can temporarily worsen physical appearance [19]. Compliance is the major limiting factor in long-term success with minoxidil therapy.

Table 2.

Summary of clinical treatment response in each study

 Summary of clinical treatment response in each study
 Summary of clinical treatment response in each study

LLLT has been examined as a possible alternative therapy to treating AGA. Studies have shown that LLLT has similar efficacy to traditional minoxidil therapy, with far fewer adverse effects. In several studies, LLLT was found to improve hair density more than minoxidil [20‒22]. Darwin et al. [22] performed a review of clinical trials involving LLLT, and of the 13 human studies only 5 reported side effects including acne, mild paresthesia, and pruritis. Given the much milder adverse effects of LLLT compared to existing treatments, long-term compliance is greater. Drawbacks to LLLT could be the initial cost of obtaining a device, and the long-term usage required demonstrates meaningful results.

The purpose of this study was to analyze existing trials comparing combined therapy of LLLT with minoxidil to either LLLT or minoxidil monotherapy. While all these studies met the inclusion criteria, there were considerable differences in treatment length, patient population, and the method of quantifying the magnitude of effect. Most notably, there were no reported adverse effects of combination treatment. While the studies demonstrated mixed findings, there at least appears to be an early improvement seen in combined therapy with topical application of minoxidil with LLLT. Some of this could be attributed to the transient telogen effluvium that occurs after 2–3 months after 5% minoxidil use [17]. During the later stages of treatment (after 6 months), there does not appear to be a meaningful difference between the minoxidil and LLLT treatment groups compared to combined therapy. It could be reasonably concluded that LLLT used with minoxidil has an early treatment benefit, but in the later treatment stage both therapies appear to have similar results in improving hair growth. Future studies should aim at standardizing the treatment protocols for more accurate comparison between groups. Furthermore, direct comparison between male and female populations would be useful to determine if there is greater efficacy in either population. It would also be of benefit to assess outcomes in different ethnic populations.

Ethical approval and consent were not required as this study was based on publicly available data.

The authors have no conflicts of interest to declare.

No funding sources for this research.

Michael A. Kaiser wrote, edited, and proofread the paper, and is the corresponding author. Stephanie M. Almeida helped write and proofread the paper. Mario Rodriguez helped write and proofread the paper. Najy Issa helped research the articles for the paper and helped write part of the paper. Naiem T. Issa helped proofread, research, and write the paper. Joaquin J. Jimenez oversaw the research and writing of the paper, helped edit the paper, and provided some of the research for the paper.

The data are available on PubMed in the referenced articles. The corresponding author can assist in further investigation of the data used in this review.

1.
Tosti A, Camaeho Martinez F, Dawber R. Management of androgenetic alopecia. J Eur Acad Dermatol Venereol. 1999;12(3):205–14.
2.
Herz-Ruelas ME, Álvarez-Villalobos NA, Millán-Alanís JM, León-Gutiérrez HD, Ocampo-Garza SS, Gómez-Flores M, et al. Efficacy of intralesional and oral dutasteride in the treatment of androgenetic alopecia: a systematic review. Skin Appendage Disord. 2020;6(6):338–45.
3.
Blumeyer A, Tosti A, Messenger A, Reygagne P, Del Marmol V, Spuls PI, et al. Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men. J Dtsch Dermatol Ges. 2011;9:S1–57.
4.
Egger A, Resnik SR, Aickara D, Maranda E, Kaiser M, Wikramanayake TC, et al. Examining the safety and efficacy of low-level laser therapy for male and female pattern hair loss: a review of the literature. Skin Appendage Disord. 2020;6(5):259–67.
5.
Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J Am Acad Dermatol. 2008;59(4):547–66.
6.
Messenger A, Rundegren J. Minoxidil: mechanisms of action on hair growth. Br J Dermatol. 2004;150(2):186–94.
7.
Suchonwanit P, Thammarucha S, Leerunyakul K. &#x3c;p&amp;gt;Minoxidil and its use in hair disorders: a review&amp;lt;/p&amp;gt;. Drug Des Devel Ther. 2019;13:2777–86.
8.
Navarro MR, Asín M, Martínez MA, Martínez AM, Molina C, Moscoso L. Management of androgenetic alopecia: a comparative clinical study between plasma rich in growth factors and topical minoxidil. Eur J Plast Surg. 2016;39(3):173–80.
9.
Olsen EA, Weiner MS, Amara IA, DeLong ER. Five-year follow-up of men with androgenetic alopecia treated with topical minoxidil. J Am Acad Dermatol. 1990;22(4):643–6.
10.
Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR. Low level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med. 2014;46(2):144–51.
11.
Wikramanayake TC, Rodriguez R, Choudhary S, Mauro LM, Nouri K, Schachner LA, et al. Effects of the Lexington LaserComb on hair regrowth in the C3H/HeJ mouse model of alopecia areata. Lasers Med Sci. 2012;27(2):431–6.
12.
Zarei M, Wikramanayake TC, Falto-Aizpurua L, Schachner LA, Jimenez JJ. Low level laser therapy and hair regrowth: an evidence-based review. Lasers Med Sci. 2016;31(2):363–71.
13.
Esmat SM, Hegazy RA, Gawdat HI, Abdel Hay RM, Allam RS, El Naggar R, et al. Low level light minoxidil 5% combination versus either therapeutic modality alone in management of female patterned hair loss: a randomized controlled study. Lasers Surg Med. 2017;49(9):835–43.
14.
Liu Y, Jiang L-l, Liu F, Qu Q, Fan Z-x, Guo Z, et al. Comparison of low-level light therapy and combination therapy of 5% minoxidil in the treatment of female pattern hair loss. Lasers Med Sci. 2021;36(5):1085–93.
15.
Faghihi G, Mozafarpoor S, Asilian A, Mokhtari F, Esfahani A, Bafandeh B, et al. The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia. Indian J Dermatol Venereol Leprol. 2018;84(5):547–53.
16.
Ferrara F, Kakizaki P, de Brito FF, Contin LA, Machado CJ, Donati A. Efficacy of minoxidil combined with photobiomodulation for the treatment of male androgenetic alopecia. A double-blind half-head controlled trial. Lasers Surgery Med. 2021;53(9):1201–7.
17.
Mahe YF, Cheniti A, Tacheau C, Antonelli R, Planard Luong L, Bernard S, et al. Low-level light therapy downregulates scalp inflammatory biomarkers in men with androgenetic alopecia and boosts minoxidil 2% to bring a sustainable hair regrowth activity. Lasers Surg Med. 2021;53(9):1208–19.
18.
Goren A, Naccarato T. Minoxidil in the treatment of androgenetic alopecia. Dermatol Ther. 2018;31(5):e12686.
19.
Randolph M, Tosti A. Oral minoxidil treatment for hair loss: a review of efficacy and safety. J Am Acad Dermatol. 2021;84(3):737–46.
20.
Kim H, Choi JW, Kim JY, Shin JW, Lee S, Huh CH. Low-level light therapy for androgenetic alopecia: a 24-week, randomized, double-blind, sham device–controlled multicenter trial. Dermatol Surg. 2013;39(8):1177–83.
21.
Leavitt M, Charles G, Heyman E, Michaels D. HairMax LaserComb® laser phototherapy device in the treatment of male androgenetic alopecia. Clin Drug Invest. 2009;29(5):283–92.
22.
Darwin E, Heyes A, Hirt PA, Wikramanayake TC, Jimenez JJ. Low-level laser therapy for the treatment of androgenic alopecia: a review. Lasers Med Sci. 2018;33(2):425–34.